Unlocking the Potential of AI For Fatty Liver Treatments

ReviveMed, a Massachusetts Institute of Technology (MIT) spinout, is using artificial intelligence (AI) to unlock the power of metabolomics to discover new therapies to treat diseases. Metabolomics is the large-scale study of small molecules like glucose or cholesterol produced by cellular activity. ReviveMed’s platform could help pharmaceutical companies redesign existing drugs or develop new drugs to help patients suffering from disease. The Cambridge, MA-based company recently raised funding to help further develop its AI solution, closing an oversubscribed seed round of $1.5 million. Rivas Capital led the round, which also included participation from several institutional investors including TechU, Team Builder Ventures, and WorldQuant Ventures. The funding will go toward obtaining additional metabolomics data for patients. “If you want genomic sequencing or RNA data, there are lots of databases available,” Leila Pirhaji, founder and CEO of ReviveMed, told MD+DI. “However, that’s not the case for metabolomics data. We’re actually spending some of our funding [from the seed round] to collect data from patients and controls.” Pirhaji, who formed ReviveMed while in in the midst of obtaining her PhD, said the company will first target non-alcohol fatty liver disease, which currently impacts more than 30% of people in the U.S. and 10% of those in the U.K. If left untreated, the disease can lead to cirrhosis and liver failure. The prevalence of non-alcohol fatt...
Source: MDDI - Category: Medical Devices Authors: Tags: Software Source Type: news